Inventor · disambiguated record
Django Sussman
Also filed as: SUSSMAN DJANGO
19 granted patents·20 pending applications·140 citations·filing 2009–2023
94Inventor score
Top patents by PatentIndex Score
39 records- 0196US8163551B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationALLEY STEPHEN C·Filed 2009·Granted Apr 24, 2012·48 cites·64 claims
- 0295US11078291B2BCMA antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2019·Granted Aug 3, 2021·8 cites·66 claims
- 0393US9816069B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEATTLE GENETICS INC·Filed 2015·Granted Nov 14, 2017·6 cites·20 claims
- 0493US8993326B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEATTLE GENETICS INC·Filed 2013·Granted Mar 31, 2015·9 cites·20 claims
- 0591US9061074B2Variant target binding agents and uses thereofSEATTLE GENETICS INC·Filed 2013·Granted Jun 23, 2015·13 cites·19 claims
- 0691US8574907B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationALLEY STEPHEN C·Filed 2012·Granted Nov 5, 2013·19 cites·27 claims
- 0789US11767365B2BCMA antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2021·Granted Sep 26, 2023·1 cites·73 claims
- 0888US11319526B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEAGEN INC·Filed 2019·Granted May 3, 2022·2 cites·63 claims
- 0987US10443035B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEATTLE GENETICS INC·Filed 2017·Granted Oct 15, 2019·2 cites·12 claims
- 1086US9587019B2CD33 antibodies and use of same to treat cancerSEATTLE GENETICS INC·Filed 2013·Granted Mar 7, 2017·7 cites·28 claims
- 1186US9228026B2Humanized antibodies to LIV-1 and use of same to treat cancerSMITH MARIA LEIA·Filed 2011·Granted Jan 5, 2016·13 cites·17 claims
- 1285USRE48959EHumanized antibodies to LIV-1 and use of same to treat cancerSEAGEN INC·Filed 2011·Granted Mar 8, 2022·4 cites·124 claims
- 1384US2024247059A1Humanized antibodies to liv-1 and use of same to treat cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 1484US2024109975A1Bcma antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2023·Application pending·0 cites
- 1582US11325980B2Combination therapy using a LIV1-ADC and a chemotherapeuticSEATTLE GENETICS INC·Filed 2017·Granted May 10, 2022·2 cites·12 claims
- 1682US9783608B2Humanized antibodies to LIV-1 and use of same to treat cancerSEATTLE GENETICS INC·Filed 2015·Granted Oct 10, 2017·3 cites·18 claims
- 1781US2024084031A1Variant target binding agents and uses thereofSEAGEN INC·Filed 2022·Application pending·0 cites
- 1881US2023242648A1Antibodies to integrin avb6 and use of same to treat cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 1980US2023055475A1Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEAGEN INC·Filed 2022·Application pending·0 cites
- 2078US10787514B2CD33 antibodies and use of same to treat cancerSEATTLE GENETICS INC·Filed 2017·Granted Sep 29, 2020·1 cites·24 claims
- 2176US10912842B2CD123 antibodies and conjugates thereofSEATTLE GENETICS INC·Filed 2016·Granted Feb 9, 2021·1 cites·53 claims
- 2275US10407505B2Variant target binding agents and uses thereofSEATTLE GENETICS INC·Filed 2016·Granted Sep 10, 2019·1 cites·20 claims
- 2372US2021340260A1Antibodies to integrin avb6 and use of same to treat cancerSEAGEN INC·Filed 2021·Application pending·0 cites
- 2470US2023218776A1Anti-ntb-a antibodies and related compositions and methodsSEAGEN INC·Filed 2022·Application pending·0 cites
- 2569US2020165335A1Humanized antibodies to liv-1 and use of same to treat cancerSEATTLE GENETICS INC·Filed 2020·Application pending·0 cites
- 2668US2023235083A1Combination therapy using a liv1-adc and a chemotherapeuticSEAGEN INC·Filed 2022·Application pending·0 cites
- 2768US2019023801A1Bcma antibodies and use of same to treat cancer and immunological disordersSEATTLE GENETICS INC·Filed 2018·Application pending·0 cites
- 2868US2021047404A1Cd33 antibodies and use of same to treat cancerSEATTLE GENETICS INC·Filed 2020·Application pending·0 cites
- 2966US2019194338A1Bcma antibodies and use of same to treat cancer and immunological disordersSEATTLE GENETICS INC·Filed 2017·Application pending·0 cites
- 3065US2020062857A1Variant target binding agents and uses thereofSEATTLE GENETICS INC·Filed 2019·Application pending·0 cites
- 3165US2020031938A1Antibodies to integrin avb6 and use of same to treat cancerSEATTLE GENETICS INC·Filed 2019·Application pending·0 cites
- 3263US2017233484A1Bcma antibodies and use of same to treat cancer and immunological disordersSEATTLE GENETICS INC·Filed 2017·Application pending·0 cites
- 3360US2018079810A1Humanized Antibodies To LIV-1 And Use Of Same To Treat CancerSEATTLE GENETICS INC·Filed 2017·Application pending·0 cites
- 3460US2021128742A1CD123 Antibodies and Conjugates ThereofSEAGEN INC·Filed 2021·Application pending·0 cites
- 3558US2013309223A1CD33 Antibodies And Use Of Same To Treat CancerSEATTLE GENETICS INC·Filed 2013·Application pending·0 cites
- 3656US11351269B2Anti-NTB-A antibodies and related compositions and methodsSEAGEN INC·Filed 2016·Granted Jun 7, 2022·0 cites·90 claims
- 3752US2021228676A1Combination Therapy With LIV1-ADC and PD-1 AntagonistSEAGEN INC·Filed 2020·Application pending·0 cites
- 3850US11938194B2Cysteine mutated antibodies for conjugationSEAGEN INC·Filed 2018·Granted Mar 26, 2024·0 cites·15 claims
- 3935US2019381171A1Co-use of anti-bcma antibody and antibody-coupled t cell receptor (actr) in cancer therapy and b cell disordersUNUM THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Django Sussman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →